Tissue inhibitor lod marker linked to tissue repair, inflammation, and scar formation. In liver testing, it is mainly discussed as a fibrosis marker because liver fibrosis is the buildup of scar-like tissue after long-term liver injury. TIMP-1 does not diagnose a liver disease by itself, but higher levels can suggest more active matrix remodeling, especially when interpreted with other fibrosis markers, liver enzymes, platelet count, imaging, and medical history.
Most people encounter TIMP-1 as part of a larger fibrosis assessment rather than as a stand-alone blood test. It is one of the three markers used in the Enhanced Liver Fibrosis, or ELF, test, along with hyaluronic acid and procollagen III N-terminal peptide. A result can help decide whether a person needs closer liver follow-up, elastography, specialist referral, or treatment for the underlying cause of liver injury.
- TIMP-1 is a protein involved in controlling matrix metalloproteinases, enzymes that help break down extracellular matrix.
- High TIMP-1 can occur with liver fibrosis, but it can also rise with inflammation, tissue injury, cancer, and other non-liver conditions.
- TIMP-1 is usually more useful in a fibrosis panel, such as the ELF test, than as a single isolated number.
- There is no universal “normal” TIMP-1 range because values depend on the assay, sample type, and reporting laboratory.
- A high result should be interpreted with liver enzymes, platelet count, bilirubin, albumin, INR, imaging, and the reason the test was ordered.
- Urgent care is needed for jaundice with confusion, vomiting blood, black stools, severe abdominal swelling, or signs of liver failure.
Table of Contents
- What TIMP-1 Measures
- Why the TIMP-1 Test Is Ordered
- How TIMP-1 Results Are Reported
- What High TIMP-1 Can Mean
- What Can Affect TIMP-1 Results
- How TIMP-1 Compares With Other Fibrosis Tests
- What to Do After an Abnormal Result
What TIMP-1 Measures
TIMP-1 is a protein that helps regulate matrix metalloproteinases, often called MMPs. MMPs are enzymes that break down parts of the extracellular matrix, the support structure around cells. The extracellular matrix is not just “filler.” It helps tissues hold their shape, repair injury, and maintain normal architecture.
Fibrosis develops when tissue repair becomes excessive or poorly controlled. In the liver, repeated injury from fat buildup, alcohol, viral hepatitis, autoimmune disease, bile duct disease, iron overload, some medications, or other causes can activate scar-forming cells. These cells produce collagen and other matrix proteins. Over time, scar tissue can distort the liver’s structure and make it harder for blood to flow normally through the organ.
TIMP-1 matters because it helps slow matrix breakdown. When TIMP-1 activity is higher, scar tissue may be less easily broken down. That does not mean TIMP-1 is “bad” in every situation. The body needs TIMP-1 for normal tissue repair and controlled healing. The concern in chronic liver disease is persistent elevation, especially when it appears alongside other signs of ongoing fibrosis.
In liver fibrosis testing, TIMP-1 is considered a direct fibrosis marker. Direct markers reflect processes involved in scar formation or matrix turnover. This differs from indirect markers, such as AST, ALT, platelet count, albumin, and INR, which suggest liver injury or impaired liver function but do not measure scar-matrix biology directly.
A clinician may interpret TIMP-1 alongside common liver blood tests such as ALT, AST, alkaline phosphatase, GGT, bilirubin, albumin, and INR. These are often reviewed together in a liver function tests panel, although the phrase “liver function” can be misleading because some markers show injury rather than true liver function.
TIMP-1 can be measured in serum or plasma, but the exact value depends on the laboratory method. For that reason, a number from one lab should not be compared loosely with a number from another lab unless the same assay and reference system are used.
Why the TIMP-1 Test Is Ordered
The TIMP-1 test is usually ordered to help assess liver fibrosis risk, not to screen the general population. Many people with early or moderate liver fibrosis feel well and have no obvious symptoms. Routine liver enzymes can also be normal or only mildly abnormal, even when fibrosis is present. This is one reason fibrosis markers and noninvasive liver tests have become more important.
A doctor may consider TIMP-1 or a TIMP-1-containing panel when someone has a known or suspected chronic liver condition, especially when the next question is whether scarring is mild or advanced. Common situations include metabolic dysfunction-associated steatotic liver disease, formerly often called NAFLD or fatty liver disease; chronic hepatitis B or C; alcohol-related liver disease; autoimmune hepatitis; primary biliary cholangitis; primary sclerosing cholangitis; hemochromatosis; and unexplained abnormal liver tests.
TIMP-1 is best known clinically as one of the three biomarkers in the Enhanced Liver Fibrosis test. The ELF test combines TIMP-1, hyaluronic acid, and procollagen III N-terminal peptide into a score. Each marker reflects a different part of extracellular matrix turnover. TIMP-1 relates to inhibition of matrix breakdown, hyaluronic acid reflects matrix metabolism and liver sinusoidal handling, and PIIINP reflects collagen formation.
The ELF test is more clinically useful than a stand-alone TIMP-1 value because a combined score reduces some of the noise that affects any single marker. For example, if TIMP-1 is mildly high because of inflammation outside the liver, the other two markers and the full clinical picture may prevent overinterpretation.
A clinician may order fibrosis testing when a first-line score is indeterminate. For example, the FIB-4 index uses age, AST, ALT, and platelet count to estimate the chance of advanced fibrosis. FIB-4 is convenient because it uses common lab results, but it can be less clear in younger adults, older adults, and people with abnormal platelet counts for reasons unrelated to liver disease. In those cases, a second-line test such as ELF or elastography may help.
TIMP-1 testing may also be used in research, drug trials, or specialty liver clinics to track fibrosis biology over time. In routine care, doctors usually focus less on the isolated TIMP-1 number and more on whether the overall fibrosis assessment suggests low, intermediate, or high risk.
How TIMP-1 Results Are Reported
TIMP-1 results may appear as an individual concentration or as part of a calculated fibrosis score. The format matters because the interpretation is different.
A stand-alone TIMP-1 concentration is usually reported with a lab-specific reference interval. The unit may be ng/mL, μg/L, or another equivalent concentration unit depending on the assay. A result marked high means it is above that laboratory’s reference range, not necessarily that the person has advanced liver fibrosis.
An ELF report usually gives a calculated score rather than asking the patient or clinician to interpret TIMP-1 alone. The score combines three markers mathematically. Some reports also show the individual marker values, while others emphasize the final score and risk category.
| Result format | What it shows | Main limitation |
|---|---|---|
| Stand-alone TIMP-1 | Amount of TIMP-1 protein in the blood sample | Not specific for liver fibrosis and highly assay-dependent |
| ELF score | Combined fibrosis score using TIMP-1, hyaluronic acid, and PIIINP | Cutoffs depend on population, guideline, and clinical setting |
| Research fibrosis panel | May combine TIMP-1 with other experimental or specialty markers | May not be validated for everyday clinical decisions |
There is no single universal TIMP-1 “optimal range” for liver health. This is different from some common blood tests where broad reference intervals are widely recognized. TIMP-1 assays can differ by antibody design, calibration, sample handling, and whether the sample is serum or plasma. A mild elevation from one lab may not equal the same degree of elevation from another lab.
For ELF scores, some guidance uses specific thresholds. In the NICE NAFLD guideline, an ELF score of 10.51 or above is used to identify advanced liver fibrosis in people with NAFLD, and people below that threshold are generally considered unlikely to have advanced fibrosis in that specific pathway. Other clinical settings may use different categories, especially when the test is being used for prognosis, specialist referral, or monitoring rather than initial assessment.
A useful way to read the report is to ask three questions:
- Was TIMP-1 measured alone or as part of a validated score?
- What reference interval or cutoff did this laboratory use?
- Does the result match the rest of the liver picture?
A high TIMP-1 result with high ELF score, low platelets, high FIB-4, abnormal liver stiffness, or signs of portal hypertension is more concerning than a mildly high TIMP-1 result with normal imaging, normal platelet count, and no known chronic liver disease.
What High TIMP-1 Can Mean
High TIMP-1 means the blood level is above the reporting laboratory’s expected range or is contributing to a higher fibrosis score. In liver care, the main concern is that high TIMP-1 may reflect active scar formation or reduced scar breakdown. It does not identify the cause of liver injury.
In chronic liver disease, higher TIMP-1 may appear when the liver is repeatedly trying to repair damage. Scar-forming cells release matrix proteins, inflammatory signals attract immune cells, and the balance between matrix production and matrix breakdown shifts. TIMP-1 can rise as part of that process.
A high TIMP-1 result may fit with liver fibrosis when it appears with other findings such as:
- Low or falling platelet count
- Enlarged spleen on imaging
- High liver stiffness on elastography
- Persistently abnormal AST, ALT, GGT, or alkaline phosphatase
- High bilirubin or abnormal bile duct markers
- Low albumin or prolonged INR in more advanced disease
- Known chronic hepatitis, MASH, alcohol-related liver disease, or cholestatic liver disease
TIMP-1 is not specific enough to separate these causes. A person with fatty liver disease may need evaluation of weight, waist size, diabetes risk, triglycerides, HDL cholesterol, blood pressure, medications, and alcohol intake. A person with high liver enzymes and iron overload patterns may need iron studies. Someone with cholestatic markers may need bile duct imaging or autoimmune testing.
High TIMP-1 can also occur outside liver fibrosis. TIMP-1 is involved in inflammation, tissue remodeling, wound healing, and cell signaling. Levels may be affected by systemic inflammatory disease, some cancers, cardiovascular remodeling, kidney disease, infection, and recent tissue injury. This is why the test should not be treated as a cancer screen, a general inflammation test, or a stand-alone liver diagnosis.
A low TIMP-1 result is usually less clinically emphasized in liver fibrosis assessment. Lower values do not prove the liver is healthy, and very low values are not usually used as a treatment target. A person can have liver fat, hepatitis, or early fibrosis with a TIMP-1 value that is not obviously high.
When high TIMP-1 is more concerning
High TIMP-1 deserves closer attention when it is part of a pattern. A single abnormal result may be nonspecific, but several abnormal fibrosis signals pointing in the same direction raise the chance of clinically important scarring.
For example, a person with type 2 diabetes, fatty liver on ultrasound, an indeterminate or high FIB-4 score, and a high ELF score should usually have more structured follow-up than someone with a mildly high isolated TIMP-1 value during a temporary inflammatory illness. In the first situation, the result fits a known liver-risk pathway. In the second, repeat testing after recovery may be more informative.
Doctors often combine fibrosis markers with scores such as FIB-4 and APRI. APRI uses AST and platelet count, while FIB-4 uses age, AST, ALT, and platelet count. These scores are not perfect, but they help decide who needs further testing.
What Can Affect TIMP-1 Results
TIMP-1 is a biology marker, not a simple “liver-only” measurement. Several factors can affect the result before the blood sample is even interpreted.
Sample type and lab method are major issues. Serum and plasma can produce different values. Different commercial assays may use different antibodies or calibration systems. Reference intervals may be based on the manufacturer’s data, local lab validation, or a specific clinical population. For this reason, trends are easiest to interpret when testing is repeated through the same lab and method.
Inflammation can raise TIMP-1 because TIMP-1 participates in immune and repair pathways. A recent infection, flare of inflammatory disease, major injury, surgery, or active cancer treatment may make a result harder to interpret. This does not make the result useless, but it changes the level of confidence.
Kidney function may also matter. Many blood biomarkers shift when kidney clearance changes, inflammation is present, or overall vascular health is altered. If kidney disease is present, the clinician should interpret TIMP-1 and ELF results with caution and in context.
Age and metabolic health can influence fibrosis risk even when they do not directly “cause” a TIMP-1 result. Older age, type 2 diabetes, insulin resistance, high triglycerides, central obesity, hypertension, and sleep apnea can all increase the chance that fatty liver disease has progressed. A person with these risk factors may need fibrosis assessment even if ALT and AST are only mildly elevated.
Alcohol use can also complicate interpretation. Alcohol may raise GGT, AST, and inflammatory signals, and long-term heavy use can cause fibrosis or cirrhosis. When alcohol-related liver injury is possible, doctors often interpret TIMP-1 with patterns such as AST/ALT ratio, GGT, bilirubin, platelet count, and imaging. The AST/ALT ratio and GGT pattern can sometimes help separate alcohol-related patterns from other causes, although it is not definitive.
Medications and supplements are another consideration. Some drugs can injure the liver, trigger cholestasis, or affect inflammation. High-dose vitamin A, anabolic steroids, methotrexate, amiodarone, tamoxifen, and some herbal products are examples that may be relevant in liver assessment. Never stop a prescribed medication only because TIMP-1 is high, but bring a complete medication and supplement list to the appointment.
Fasting is usually not required for TIMP-1 itself. However, fasting may be requested if the blood draw includes glucose, insulin, triglycerides, or other metabolic tests. Follow the instructions on the lab order rather than assuming TIMP-1 has special preparation rules.
How TIMP-1 Compares With Other Fibrosis Tests
TIMP-1 has value because it reflects matrix remodeling, but it is only one piece of fibrosis assessment. Liver fibrosis is best evaluated with layers of information. Each test answers a different question.
Routine liver enzymes show injury or cholestasis patterns. ALT and AST can rise when liver cells are irritated or damaged, while alkaline phosphatase and GGT can rise with bile duct stress or cholestasis. These tests are useful, but normal liver enzymes do not rule out significant fibrosis. A person can have advanced scarring with only modest enzyme changes.
Platelet count is an indirect clue. As fibrosis progresses and portal pressure rises, the spleen may enlarge and platelet count may fall. This is why platelet count appears in FIB-4 and APRI. A low platelet count has many possible causes, but in the right setting it can be an important liver clue.
Synthetic function markers show how well the liver performs certain jobs. Albumin and INR are especially important when advanced chronic liver disease is suspected. Albumin may fall when the liver makes less protein, and INR may rise when clotting factor production is impaired. The combination of albumin and INR often gives more information about advanced liver function than TIMP-1 alone.
Elastography measures liver stiffness. Transient elastography, shear wave elastography, and magnetic resonance elastography estimate stiffness, which often rises with fibrosis. Stiffness can also rise temporarily with inflammation, congestion, cholestasis, or recent heavy alcohol use, so the number still needs interpretation.
Liver biopsy directly samples liver tissue, but it is invasive and has sampling limitations. It may still be needed when the diagnosis is unclear, autoimmune disease is suspected, multiple liver conditions overlap, or treatment decisions require histology. Noninvasive tests have reduced the need for biopsy in many routine fibrosis pathways.
| Test or marker | Main use | Best interpreted with |
|---|---|---|
| TIMP-1 | Direct marker of matrix remodeling and fibrosis biology | ELF score, liver enzymes, platelets, imaging, diagnosis |
| ELF test | Blood-based fibrosis score using TIMP-1, hyaluronic acid, and PIIINP | Clinical risk factors, FIB-4, elastography |
| FIB-4 | First-line estimate of advanced fibrosis risk | Age, AST, ALT, platelet count, second-line tests |
| APRI | Simple fibrosis estimate, historically common in viral hepatitis | AST, platelet count, disease context |
| Elastography | Imaging-based estimate of liver stiffness | Inflammation status, cholestasis, congestion, body habitus |
| Liver biopsy | Direct tissue assessment when uncertainty remains | Specialist evaluation and clear clinical reason |
The ELF test is closely related to TIMP-1 because TIMP-1 is one of its components. A separate Enhanced Liver Fibrosis test result is often easier to act on than isolated TIMP-1 because ELF has studied cutoffs and clinical pathways.
The other ELF markers can also add context. Hyaluronic acid may rise when liver matrix turnover and clearance are altered. Procollagen III N-terminal peptide reflects collagen formation. When all three markers move together, the fibrosis signal is usually stronger than when only one is abnormal.
What to Do After an Abnormal Result
An abnormal TIMP-1 result should lead to a structured review, not panic. The next step depends on why the test was ordered, how high the result is, and whether other markers point toward liver fibrosis.
Start by confirming the result format. If it is a stand-alone TIMP-1 value, compare it only with that lab’s reference interval. Ask whether the sample was serum or plasma and whether the lab has used the same method for previous tests. If it is part of an ELF score, focus on the score interpretation and risk category rather than trying to interpret TIMP-1 alone.
Next, review the liver pattern. ALT and AST suggest liver cell injury. Alkaline phosphatase, GGT, and bilirubin suggest bile duct or cholestatic patterns when elevated together. Albumin and INR help assess synthetic function. Platelet count can hint at portal hypertension or advanced scarring when low. A hepatic function panel can provide many of these markers, but platelet count and INR may require separate orders.
Then look for the cause. Fibrosis is a response to injury, so reducing the driver is the most important treatment strategy. In fatty liver disease, the plan may include weight loss when appropriate, improved glucose control, triglyceride management, regular physical activity, sleep apnea treatment, and limiting alcohol. In viral hepatitis, antiviral treatment can reduce progression. In autoimmune or cholestatic disease, disease-specific therapy matters. In iron overload, phlebotomy or specialist-directed care may be needed.
A clinician may order follow-up tests such as:
- Repeat liver panel and complete blood count
- FIB-4 or APRI calculation
- Hepatitis B and C testing
- Iron studies, including ferritin and transferrin saturation
- Autoimmune liver markers when the pattern fits
- Ultrasound or elastography
- MRI-based testing in selected cases
- Specialist hepatology referral if advanced fibrosis is possible
Urgent symptoms should not wait for routine follow-up. Seek urgent care for yellowing of the skin or eyes with confusion, vomiting blood, black tarry stools, severe abdominal swelling, fainting, severe right upper abdominal pain with fever, or new easy bleeding. These symptoms can signal complications such as liver failure, cholangitis, gastrointestinal bleeding, or decompensated cirrhosis.
For monitoring, timing depends on the risk category. A low-risk result may be repeated in a few years in some pathways, while an indeterminate or high-risk result may need elastography, specialist review, or closer monitoring. Repeating TIMP-1 too soon after an infection, surgery, flare, or medication-related liver injury may produce confusing results. When possible, repeat testing should occur after temporary inflammatory problems have settled.
Lifestyle changes should be specific and realistic. For many people with metabolic fatty liver disease, losing 5% of body weight can reduce liver fat, while larger weight loss may be needed to improve inflammation and fibrosis risk. Resistance training and aerobic activity both help metabolic health. Alcohol reduction is often recommended even when alcohol is not the main cause of liver injury. Supplements should be treated cautiously because some can harm the liver or interact with medications.
A high TIMP-1 result is most useful when it starts a better conversation: What is injuring the liver? Is fibrosis likely to be advanced? Do we need elastography or specialist care? What can be changed now to lower future risk? The number itself is not the diagnosis. The pattern around it is what guides care.
References
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease 2023 (Guidance)
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update 2021 (Guideline)
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) 2022 (Guideline)
- Cut loose TIMP-1: an emerging cytokine in inflammation 2023 (Review)
- The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity 2010 (Review)
- Non-alcoholic fatty liver disease (NAFLD): assessment and management 2016 (Guideline)
Disclaimer
TIMP-1 and ELF results should be interpreted by a qualified healthcare professional who can review your full medical history, medications, imaging, and other blood tests. A high result does not diagnose cirrhosis or identify the cause of liver injury by itself. Seek urgent medical care for jaundice with confusion, vomiting blood, black stools, severe abdominal swelling, or other symptoms that could signal serious liver complications.
